Open Access Open Access  Restricted Access Subscription Access

QBD in Analytical Method Development and Validation: A Review

Obaid Shaikh, Zahid Zaheer, Rana Z Ahmad, Tazim Shaikh

Abstract


Quality advisedly is the current approach to the category of prescription drugs. The aim of the pharmaceutical development is to provide a prime quality factory-made product and its manufacturing technique to often deliver the approaching performance of the products. Quality can not be tested into product however quality ought to be inbuilt advisedly. It's a vital part of the trendy approach to pharmaceutical quality. During this construct of QBD, it's essential to stipulate need product expression profile [Target Product Profile ( TPP&#41, Object Product Quality Profile (OPQP)] and spot important quality attributed (CQA). On the bottom of this, we are able to style the merchandise formulation and method to fulfil the merchandise qualities. This lands up in recognizing the impact of raw materials [critical material attributes (CMA)], necessary technique parameters (CPP) on the CQA sand Identification and management sources of variability.


Full Text:

PDF

References


Bhagyesh Trivedi (2012), International Journal of Pharmacy and Pharmaceutical Sciences, Volume 4, Issue 1, pp. 17−29.

Jaiprakash N. Sangshetti, Mrinmayee Deshpande, Zahid Zaheer, Devanand B. Shinde, Rohidas Arote (2014), Arabian Journal of Chemistry, pp. 1−14.

Amit S. Patil, Anil M. Pethe (2013), IJPQA, Volume 4, Issue 2, pp. 13−19.

Nishendu P, Nadpara, Rakshit V Thumar, Vidhi N. Kalola, Parula B. Patel (2012), International Journal of Pharmaceutical Sciences Review and Research, Volume 17, Issue 2, pp. 20−28.

N.V.V.S.S. Raman, Useni Reddy Mallu, Hanimi Reddy Bapatu, “Analytical quality by design (QBD) Approach to test method development and validation in drug substance manufacturing”,

Lawrence X. Yu. (2008), Pharmaceutical Research, Volume 25, Issue 4, pp. 781−791.

Oonamcpolin (2009), “Validation of an analytical method for pharmaceutical analysis”, Mourne training services,

Mayank Nagar, Kamal Singh Panwar, V. S. Chopra, Indu Bala, Piyush Trivedi (2010), Scholars Research Library Der Pharmacia Letter, Volume 2, Issue 2, pp. 111−130.

Sandipan Roy (2012), International Journal of Pharmaceutical and biomedical research, Volume 3, Issue 2, pp. 100−108.

Nwoko valentine eziokwu (2013), Journal of Global Trends in Pharmaceutical Sciences, Volume 4, Issue 4, pp. 1257−1262.

“Food and Drug Administration CDER. Guidance for industry, Q8 pharmaceutical-development”, (2006)

Yu Lx (2008), Pharmaceutical research, Volume 25, Issue 4, pp. 781−791.

Woodcock (2004), J. Am. Pharm. Rev, pp. 1–3.

Lawrence X, Raw A, Lionberger R, Rajagopalan R, Lee L, Holcombe F, Patel R, Fang F, Sayeed V, Schwartz P, Adams P, and Buehler G. U.S (2007). J. Generic Med, Volume 4, pp. 239–248.

Nasr M. (2004), “Risk-based CMC review paradigm. The advisory committee for pharmaceutical science meeting”,

“Food and Drug Administration CDER. Guidance for industry: Immediate release solid oral dosage forms scaleup and post-approval changes: Chemistry, manufacturing, and controls, in vitro dissolution testing, and in vivo Bioequivalence documentation”, (1995),

Food and Drug Administration CDER. Guidance for industry: Modified release solid oral dosage forms scaleup and post-approval changes: Chemistry, manufacturing, and controls, in-vitro dissolution testing, and in vivo Bio equivalence documentation, (1997)


Refbacks

  • There are currently no refbacks.